Lyndra offers the LYNX™ platform, a clinically validated technology that enables long‑acting oral drug delivery by encapsulating active ingredients in a proprietary matrix for controlled, sustained release. This reduces peak‑trough variability, improves efficacy and safety, and allows less‑frequent dosing schedules that boost patient adherence. The platform is compatible with a wide range of small‑molecule therapeutics and can be integrated by pharmaceutical and biotech companies without reformulating the active molecule.
Funding
$293.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many oral medications require daily dosing, leading to fluctuating drug concentrations that can cause side effects, reduced efficacy, and poor patient adherence.
Solution
Lyndra’s LYNX™ platform provides a clinically validated technology for long‑acting oral drug delivery that maintains stable therapeutic levels over extended periods. By encapsulating active ingredients in a proprietary matrix, LYNX releases the drug at a controlled rate, minimizing peak‑trough fluctuations and associated adverse events. The platform enables less‑frequent dosing schedules, which improves patient convenience and adherence. It has been evaluated in multiple human and animal studies, demonstrating safety, tolerability, and consistent dose‑release profiles across various therapeutic areas. Pharmaceutical developers can integrate LYNX into existing oral compounds to create differentiated, long‑acting formulations without redesigning the active molecule.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to develop long‑acting oral formulations for existing or pipeline drug candidates.
Features
- Proprietary matrix technology that provides controlled, sustained release of oral drugs
- Clinically validated in over 100 human dosing studies and numerous animal trials
- Demonstrated reduction in peak‑trough variability, enhancing efficacy and safety
- Enables extended dosing intervals (e.g., weekly, monthly) to improve patient adherence
- Compatible with a wide range of small‑molecule therapeutics without reformulating the active ingredient
- Scalable manufacturing process suitable for commercial drug development